Subcutaneous Insulin Regimen for Mild Diabetic Ketoacidosis
For stable patients with mild diabetic ketoacidosis, subcutaneous rapid-acting insulin analogs (such as lispro, aspart, or glulisine) should be administered at a dose of 0.2 units/kg initially, followed by 0.1-0.2 units/kg every 1-2 hours, combined with aggressive fluid management. 1
Initial Assessment and Eligibility
- Patients with mild to moderate DKA who are stable, alert, and without severe complications are candidates for subcutaneous insulin treatment 1
- Ensure adequate fluid replacement is provided alongside subcutaneous insulin therapy 1
- Frequent point-of-care blood glucose monitoring is essential (every 1-2 hours) 2
Recommended Insulin Protocol
Initial Dosing
- Administer rapid-acting insulin analog (lispro, aspart, or glulisine) at 0.2 units/kg as initial bolus dose 3
- Consider adding a single dose of basal insulin (glargine) at 0.2 units/kg upon therapy initiation to prevent rebound hyperglycemia 3
Maintenance Dosing
- Continue with rapid-acting insulin at 0.1-0.2 units/kg every 1-2 hours until DKA resolution 4, 5
- Alternative approach: 0.1-0.2 units/kg every 3 hours with less frequent monitoring 3
Fluid Management
- Begin with isotonic saline at a rate of 15-20 ml/kg/h during the first hour 6
- Continue fluid replacement to correct estimated deficits within the first 24 hours 7
- Monitor fluid input/output and hemodynamic parameters regularly 7
Monitoring Requirements
- Check blood glucose every 1-2 hours (or every 3 hours with alternative protocol) 3
- Monitor electrolytes, particularly potassium, every 2-4 hours 7
- Assess for resolution parameters: glucose <200 mg/dL, serum bicarbonate ≥18 mEq/L, venous pH >7.3, and anion gap ≤12 mEq/L 7
Transition to Maintenance Insulin
- Once DKA resolves and the patient can eat, transition to a multiple-dose regimen 7
- A basal-bolus regimen with glargine and rapid-acting insulin analogs is preferred over NPH and regular insulin 8
- Administer basal insulin 2-4 hours before discontinuing the frequent subcutaneous insulin doses to prevent rebound hyperglycemia 1
Advantages of Subcutaneous Approach
- Similar efficacy to intravenous insulin for mild to moderate DKA 5
- Cost-effective alternative that may avoid ICU admission 9, 4
- Technically simpler treatment with comparable time to DKA resolution 4, 5
- Lower rates of hypoglycemia when transitioning to basal-bolus regimens compared to NPH/regular insulin 8
Potential Pitfalls and Considerations
- This approach is not appropriate for patients with severe DKA, altered mental status, or hemodynamic instability 2, 7
- Ensure adequate staffing for frequent monitoring and insulin administration 3
- Monitor closely for hypoglycemia, especially during transition to maintenance insulin 8
- Treat any underlying precipitating causes of DKA (infection, myocardial infarction, stroke) 2
This subcutaneous insulin approach has been shown to be as effective as intravenous insulin in resolving mild to moderate DKA, with comparable times to resolution (10-14.8 hours) and similar safety profiles 4, 5.